We don't need to be comparing this to Viagra sales now that it is competing against generics; we should be looking at the peek sales with exclusive marketing rights and scaling up because it works better, and scaling up again because of the lower side effects, and therefore scaling up again for the repeat customers. IMHO 25% of $2Bn is a conservative estimate, it could do more than the original ever did
We don't need to be comparing this to Viagra sales now that...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LTP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
-0.040(3.20%) |
Mkt cap ! $102.5M | |||
| Open | High | Low | Value | Volume |
| $1.28 | $1.28 | $1.18 | $682.7K | 564.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 155 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 815 | 1 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| LTP (ASX) Chart |